Ozanimod showed a rapid onset of action and efficacy as extended induction therapy in patients with ulcerative colitis nonresponsive to biologics.

In a US study, researchers found that 35% of adults with IBD screened positive for spondyloarthritis, despite having no known SpA diagnosis.

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

BRIDGEWATER, NJ, USA and BENGALURU, India I4, 2025 I Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEKtm (ustekinumab-kfce) is now ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI for all indications matching the reference ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently approved ...